What were the key takeaways from Canopy Growth’s earnings call?

What is the revenue and EPS growth rate for Canopy Growth year over year?

What is Canopy Growth's gross profit margin?

What guidance did Canopy Growth's management provide for the next earnings period?

What does Canopy Growth do and what are its main business segments?

What is Canopy Growth's latest dividend and current dividend yield?

What were the key takeaways from Canopy Growth's earnings call?

Did Canopy Growth beat or miss consensus estimates last quarter?

- **Canadian dominance**: 30% revenue growth in adult-use, 17% medical expansion, and 12% cannabis segment growth.
- **Cost efficiency**: CAD 21M+ savings vs. CAD 20M target, supporting 2026 EBITDA positivity.
- **International turnaround**: Europe restructuring to 100% Canadian-sourced flower, positioning for H2 profitability.


**【Management Opening Remarks】**
- Canopy Growth issued Q2 FY2026 financial results with CAD 51 million in cannabis net revenue, up 12% year-over-year. 
- The company achieved CAD 298 million in cash and cash equivalents, exceeding debt balances by CAD 70 million.
- Adjusted EBITDA loss narrowed significantly, driven by cost-saving initiatives and improved gross margins.

**【CEO Summary Section】**
- Canadian adult-use cannabis revenue grew 30% YoY, driven by Claybourne-infused pre-rolls and Tweed all-in-one vapes.
- Medical cannabis revenue increased 17% YoY, supported by patient registrations and product assortment expansion.
- International markets faced supply chain challenges, but Europe-focused restructuring is underway.

**【CFO Financial Commentary】**
- Q2 operating expenses declined 13% YoY, with CAD 21 million in annualized savings vs. CAD 20 million target.
- Free cash flow improved 67% YoY, reflecting debt reduction and working capital management.

**【Q&A Highlights】**
- Europe retooling to source 100% of flower from Canadian GMP facilities.
- Positive adjusted EBITDA expected in H2 FY2026 through cost management and capacity utilization.
- Storz & Bickel VZ Vaporizer sales up 5% QoQ, targeting holiday season growth.


CGC

CGC fundamentals

You can ask Aime